Genzyme's Termeer to pocket up to $221M

Tools

Genzyme CEO Henri Termeer, 2010's top biopharma whipping boy, will leave the biotech with at least $158.4 million, according to Bloomberg. Citing regulatory filings, the news service adds that Termeer will pocket $145.9 million for his stock plus $12.5 million for a change-of-control clause and up to $62.8 million for the CVR that he negotiated with Sanofi. That's quite a turnaround for an executive who was being pressured to resign from the company after Genzyme was beset by a host of manufacturing woes last year. Report